Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade

References

1. 1.↵
   2. Ostrom QT,
   3. Gittleman H,
   4. Xu J, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. Neuro Oncol 2016;18:v1–v75 doi:10.1093/neuonc/now207 pmid:28475809

   CrossRefPubMed
2. 2.↵
   2. Falk A,
   3. Fahlström M,
   4. Rostrup E, et al

   . Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology 2014;56:1031–38 doi:10.1007/s00234-014-1426-z pmid:25204450

   CrossRefPubMed
3. 3.↵
   2. Li X,
   3. Zhu Y,
   4. Kang H, et al

   . Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging. Cancer Imaging 2015;15:4 doi:10.1186/s40644-015-0039-z pmid:25889239

   CrossRefPubMed
4. 4.↵
   2. Roberts HC,
   3. Roberts TP,
   4. Ley S, et al

   . Quantitative estimation of microvascular permeability in human brain tumors: correlation of dynamic Gd-DTPA–enhanced MR imaging with histopathologic grading. Acad Radiol 2002;9:S151–55 doi:10.1016/S1076-6332(03)80425-7 pmid:12019855

   CrossRefPubMed
5. 5.↵
   2. Zhang N,
   3. Zhang L,
   4. Qiu B, et al

   . Correlation of volume transfer coefficient K^trans with histopathologic grades of gliomas. J Magn Reson Imaging 2012;36:355–63 doi:10.1002/jmri.23675 pmid:22581762

   CrossRefPubMed
6. 6.↵
   2. Vajapeyam S,
   3. Stamoulis C,
   4. Ricci K, et al

   . Automated processing of dynamic contrast-enhanced MRI: correlation of advanced pharmacokinetic metrics with tumor grade in pediatric brain tumors. AJNR Am J Neuroradiol 2017;38:170–75 doi:10.3174/ajnr.A4949 pmid:27633807

   Abstract/FREE Full Text
7. 7.↵
   2. Koob M,
   3. Girard N,
   4. Ghattas B, et al

   . The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. J Neurooncol 2016;127:345–53 doi:10.1007/s11060-015-2042-4 pmid:26732081

   CrossRefPubMed
8. 8.↵
   2. Poussaint TY,
   3. Rodriguez D

   . Advanced neuroimaging of pediatric brain tumors: MR diffusion, MR perfusion, and MR spectroscopy. Neuroimaging Clin N Am 2006;16:169–92, ix doi:10.1016/j.nic.2005.11.005 pmid:16543091

   CrossRefPubMed
9. 9.↵
   2. Pope WB,
   3. Qiao XJ,
   4. Kim HJ, et al

   . Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108:491–98 doi:10.1007/s11060-012-0847-y pmid:22426926

   CrossRefPubMed
10. 10.↵
    2. Rahman R,
    3. Hamdan A,
    4. Zweifler R, et al

    . Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol 2014;119:149–58 doi:10.1007/s11060-014-1464-8 pmid:24805151

    CrossRefPubMed
11. 11.↵
    2. Poussaint TY,
    3. Vajapeyam S,
    4. Ricci KI, et al

    . Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 2016;18:725–34 doi:10.1093/neuonc/nov256 pmid:26487690

    CrossRefPubMed
12. 12.↵
    2. Tofts PS

    . Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91–101 doi:10.1002/jmri.1880070113 pmid:9039598

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Weinmann HJ,
    3. Laniado M,
    4. Mützel W

    . Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167–72 pmid:6505043

    PubMedWeb of Science
14. 14.↵
    2. Jenkinson M,
    3. Beckmann CF,
    4. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Schindelin J,
    3. Arganda-Carreras I,
    4. Frise E, et al

    . Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676–82 doi:10.1038/nmeth.2019 pmid:22743772

    CrossRefPubMedWeb of Science
16. 16.↵
    SAS/STAT 14.1 User's Guide. July 2015. http://support.sas.com/documentation/cdl/en/statug/68162/HTML/default/viewer.htm#titlepage.htm. Updated November 2, 2015
17. 17.↵
    2. Morana G,
    3. Piccardo A,
    4. Tortora D, et al

    . Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET. Eur J Nucl Med Mol Imaging 2017;44:2084–89 doi:10.1007/s00259-017-3777-2 pmid:28752225

    CrossRefPubMed
18. 18.↵
    2. Tzika AA,
    3. Astrakas LG,
    4. Zarifi MK, et al

    . Multiparametric MR assessment of pediatric brain tumors. Neuroradiology 2003;45:1–10 doi:10.1007/s00234-002-0865-0 pmid:12525947

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Zukotynski KA,
    3. Fahey FH,
    4. Vajapeyam S, et al

    . Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. J Nucl Med 2013;54:1237–43 doi:10.2967/jnumed.112.115782 pmid:23801675

    Abstract/FREE Full Text
20. 20.↵
    2. Tensaouti F,
    3. Ducassou A,
    4. Chaltiel L, et al

    ; radiotherapy committee of the French Society for Childhood Cancer (SFCE). Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study. Br J Radiol 2016;89:20160537 doi:10.1259/bjr.20160537 pmid:27550423

    CrossRefPubMed
21. 21.↵
    2. Ho CY,
    3. Cardinal JS,
    4. Kamer AP, et al

    . Relative cerebral blood volume from dynamic susceptibility contrast perfusion in the grading of pediatric primary brain tumors. Neuroradiology 2015;57:299–306 doi:10.1007/s00234-014-1478-0 pmid:25504266

    CrossRefPubMed
22. 22.↵
    2. Ho CY,
    3. Cardinal JS,
    4. Kamer AP, et al

    . Contrast leakage patterns from dynamic susceptibility contrast perfusion MRI in the grading of primary pediatric brain tumors. AJNR Am J Neuroradiol 2016;37:544–51 doi:10.3174/ajnr.A4559 pmid:26564438

    Abstract/FREE Full Text
23. 23.↵
    2. Yeom KW,
    3. Mitchell LA,
    4. Lober RM, et al

    . Arterial spin-labeled perfusion of pediatric brain tumors. AJNR Am J Neuroradiol 2014;35:395–401 doi:10.3174/ajnr.A3670 pmid:23907239

    Abstract/FREE Full Text
24. 24.↵
    2. Abe T,
    3. Mizobuchi Y,
    4. Nakajima K, et al

    . Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition time. Springerplus 2015;4:88 doi:10.1186/s40064-015-0861-6 pmid:25793147

    CrossRefPubMed
25. 25.↵
    2. Choi HS,
    3. Kim AH,
    4. Ahn SS, et al

    . Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI. Korean J Radiol 2013;14:487–92 doi:10.3348/kjr.2013.14.3.487 pmid:23690718

    CrossRefPubMed
26. 26.↵
    2. Jensen RL,
    3. Mumert ML,
    4. Gillespie DL, et al

    . Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol 2014;16:280–91 doi:10.1093/neuonc/not148 pmid:24305704

    CrossRefPubMed
27. 27.↵
    2. Perreault S,
    3. Ramaswamy V,
    4. Achrol AS, et al

    . MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2014;35:1263–69 doi:10.3174/ajnr.A3990 pmid:24831600

    Abstract/FREE Full Text
28. 28.↵
    2. Lastowska M,
    3. Jurkiewicz E,
    4. Trubicka J, et al

    . Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours. J Neurooncol 2015;123:65–73 doi:10.1007/s11060-015-1779-0 pmid:25862008

    CrossRefPubMed
29. 29.↵
    2. Yeom KW,
    3. Mobley BC,
    4. Lober RM, et al

    . Distinctive MRI features of pediatric medulloblastoma subtypes. AJR Am J Roentgenol 2013;200:895–903 doi:10.2214/AJR.12.9249 pmid:23521467

    CrossRefPubMed
30. 30.↵
    2. Ramaswamy V,
    3. Northcott PA,
    4. Taylor MD

    . FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 2011;204:577–88 doi:10.1016/j.cancergen.2011.11.001 pmid:22200083

    CrossRefPubMed
31. 31.↵
    2. Mills SJ,
    3. Soh C,
    4. Rose CJ, et al

    . Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging–derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 2010;31:549–53 doi:10.3174/ajnr.A1844 pmid:19850765

    Abstract/FREE Full Text